Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
RGEN Stock Forecast 2025-2026
$117.54
Current Price
$6.80B
Market Cap
Buy 14
Hold 5
Sell 0
Wall St Analyst Ratings
Distance to RGEN Price Targets
+87.2%
To High Target of $220.00
+57.4%
To Median Target of $185.00
+19.1%
To Low Target of $140.00
RGEN Price Momentum
-10.5%
1 Week Change
-6.9%
1 Month Change
-4.4%
1 Year Change
-18.3%
Year-to-Date Change
-35.6%
From 52W High of $182.52
+14.1%
From 52W Low of $102.97
📊 TOP ANALYST CALLS
Did RGEN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Repligen is one of their latest high-conviction picks.
Latest RGEN Stock Price Targets & Analyst Predictions
Based on our analysis of 19 Wall Street analysts, RGEN has a bullish consensus with a median price target of $185.00 (ranging from $140.00 to $220.00). The overall analyst rating is Strong Buy (8.5/10). Currently trading at $117.54, the median forecast implies a 57.4% upside. This outlook is supported by 14 Buy, 5 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Paul Knight at Keybanc, projecting a 87.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
RGEN Analyst Ratings
14
Buy
5
Hold
0
Sell
RGEN Price Target Range
Low
$140.00
Average
$185.00
High
$220.00
Current: $117.54
Latest RGEN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for RGEN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 5, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $180.00 |
| Apr 30, 2025 | RBC Capital | Conor McNamara | Outperform | Maintains | $189.00 |
| Apr 29, 2025 | JP Morgan | Rachel Vatnsdal | Overweight | Maintains | $190.00 |
| Apr 17, 2025 | Canaccord Genuity | Hold | Maintains | $0.00 | |
| Apr 16, 2025 | Canaccord Genuity | Kyle Mikson | Hold | Maintains | $150.00 |
| Mar 18, 2025 | Evercore ISI Group | Daniel Markowitz | In-Line | Initiates | $155.00 |
| Feb 21, 2025 | JP Morgan | Rachel Vatnsdal | Overweight | Maintains | $200.00 |
| Feb 21, 2025 | Canaccord Genuity | Kyle Mikson | Hold | Maintains | $170.00 |
| Feb 21, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $180.00 |
| Feb 21, 2025 | RBC Capital | Conor McNamara | Outperform | Maintains | $205.00 |
| Jan 23, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $180.00 |
| Jan 22, 2025 | HC Wainwright & Co. | Buy | Maintains | $0.00 | |
| Dec 17, 2024 | Canaccord Genuity | Kyle Mikson | Hold | Initiates | $165.00 |
| Nov 14, 2024 | Wolfe Research | Doug Schenkel | Peer Perform | Initiates | $0.00 |
| Sep 26, 2024 | RBC Capital | Conor McNamara | Outperform | Reiterates | $205.00 |
| Aug 27, 2024 | Wells Fargo | Brandon Couillard | Overweight | Initiates | $180.00 |
| Aug 5, 2024 | Benchmark | Robert Wasserman | Hold | Reiterates | $0.00 |
| Jul 31, 2024 | RBC Capital | Conor McNamara | Outperform | Reiterates | $190.00 |
| Jul 31, 2024 | JP Morgan | Rachel Vatnsdal | Overweight | Maintains | $200.00 |
| Jul 31, 2024 | UBS | Elizabeth Garcia | Buy | Maintains | $185.00 |
Repligen Corporation (RGEN) Competitors
The following stocks are similar to Repligen based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Repligen Corporation (RGEN) Financial Data
Repligen Corporation has a market capitalization of $6.80B with a P/E ratio of 511.1x. The company generates $650.43M in trailing twelve-month revenue with a -3.5% profit margin.
Revenue growth is +10.4% quarter-over-quarter, while maintaining an operating margin of +5.6% and return on equity of -1.2%.
Valuation Metrics
Market Cap
$6.80B
Enterprise Value
$6.79B
P/E Ratio
511.1x
PEG Ratio
68.0x
Price/Sales
10.5x
Growth & Margins
Revenue Growth (YoY)
+10.4%
Gross Margin
+53.6%
Operating Margin
+5.6%
Net Margin
-3.5%
EPS Growth
+76.9%
Financial Health
Cash/Price Ratio
+10.6%
Current Ratio
6.8x
Debt/Equity
34.4x
ROE
-1.2%
ROA
+0.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Repligen Corporation (RGEN) Business Model
About Repligen Corporation
What They Do
Provides bioprocessing technologies for pharmaceuticals.
Business Model
Repligen Corporation earns revenue by developing and supplying essential bioprocessing technologies, including chromatography resins and filtration systems, to the biotechnology and pharmaceutical industries. These products are crucial for the efficient and scalable production of biologics, catering to a growing market demand for advanced therapies.
Additional Information
Located in Waltham, Massachusetts, Repligen has established a strong reputation in the bioprocessing field, supporting applications such as antibody production, gene therapy, and cell therapy. The company is well-positioned to benefit from the expanding biopharmaceutical sector, which is increasingly focused on targeted and personalized medicine.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
1,778
CEO
Mr. Olivier Loeillot
Country
United States
IPO Year
1990
Website
www.repligen.comRepligen Corporation (RGEN) Latest News & Analysis
Latest News
Quick Summary
908 Devices Inc. (Nasdaq: MASS) has appointed Dr. Christopher D. Brown, a co-founder and former CTO, to its Board of Directors, effective immediately.
Why It Matters
The appointment of a co-founder and experienced executive to the Board can enhance strategic direction and innovation, potentially boosting investor confidence and stock performance for 908 Devices.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Repligen (RGEN) reported earnings 30 days ago; investors may be looking for upcoming developments or performance indicators to assess the stock's future trajectory.
Why It Matters
Repligen's recent earnings report can influence investor sentiment and stock performance, signaling potential growth or challenges ahead, impacting investment decisions.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Repligen Corporation (NASDAQ:RGEN) published its 2024 Corporate Sustainability Report, highlighting advancements in sustainability across six areas and aligning with UN SDGs and GRI/SASB standards.
Why It Matters
Repligen's sustainability report highlights its commitment to responsible practices, aligning with global standards, which can enhance investor confidence and attract ESG-focused capital.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Repligen Corporation (NASDAQ:RGEN) will participate in several investor conferences in May 2025, highlighting its focus on bioprocessing technology.
Why It Matters
Repligen's participation in investor conferences can enhance visibility, attract interest, and potentially influence stock performance through increased investor engagement.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
RGEN reports stronger-than-expected Q1 results and raises its total revenue guidance for 2025.
Why It Matters
RGEN's strong Q1 results and raised 2025 revenue guidance signal growth potential, boosting investor confidence and likely positively impacting stock performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Investors in the Medical - Biomedical and Genetics sector are evaluating Qiagen (QGEN) and Repligen (RGEN) for value investment opportunities.
Why It Matters
The comparison of Qiagen and Repligen highlights potential investment opportunities in the Biomedical and Genetics sector, impacting stock selection and valuation strategies for investors.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About RGEN Stock
What is Repligen Corporation's (RGEN) stock forecast for 2025?
Based on our analysis of 19 Wall Street analysts, Repligen Corporation (RGEN) has a median price target of $185.00. The highest price target is $220.00 and the lowest is $140.00.
Is RGEN stock a good investment in 2025?
According to current analyst ratings, RGEN has 14 Buy ratings, 5 Hold ratings, and 0 Sell ratings. The stock is currently trading at $117.54. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for RGEN stock?
Wall Street analysts predict RGEN stock could reach $185.00 in the next 12 months. This represents a 57.4% increase from the current price of $117.54. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Repligen Corporation's business model?
Repligen Corporation earns revenue by developing and supplying essential bioprocessing technologies, including chromatography resins and filtration systems, to the biotechnology and pharmaceutical industries. These products are crucial for the efficient and scalable production of biologics, catering to a growing market demand for advanced therapies.
What is the highest forecasted price for RGEN Repligen Corporation?
The highest price target for RGEN is $220.00 from Paul Knight at Keybanc, which represents a 87.2% increase from the current price of $117.54.
What is the lowest forecasted price for RGEN Repligen Corporation?
The lowest price target for RGEN is $140.00 from at , which represents a 19.1% increase from the current price of $117.54.
What is the overall RGEN consensus from analysts for Repligen Corporation?
The overall analyst consensus for RGEN is bullish. Out of 19 Wall Street analysts, 14 rate it as Buy, 5 as Hold, and 0 as Sell, with a median price target of $185.00.
How accurate are RGEN stock price projections?
Stock price projections, including those for Repligen Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 19, 2025 10:46 AM UTC